Imbruvica (Ibrutinib): The 2026-2032 Generic Opportunity Window

AbbVie and Johnson & Johnson's blockbuster oral irreversible Bruton's tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) generated $3.60 billion in full-year 2023 global net revenues for AbbVie, with U.S. annual net revenues exceeding $2.78 billion and combined global alliance sales exceeding $7 billion. Imbruvica remains 100% brand-only in the United States today, with zero generic ibrutinib commercially approved or selling across capsule (70 mg, 140 mg) and tablet (140 mg, 280 mg, 420 mg, 560 mg) strengths. Core composition-of-matter and substance patents US 7,514,444 and US 8,008,309 expire on December 28, 2026, extended to June 28, 2027 through a six-month pediatric exclusivity extension granted under Section 505A of the FD&C Act. While secondary solid-state crystalline polymorph and formulation patents extend statutory Orange Book listings through 2033 to 2036, leading Indian generic manufacturers including Zydus Lifesciences (holding FDA tentative approval for generic tablets), Natco Pharma, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Lupin maintain active Paragraph IV ANDA filings. AbbVie's official SEC Form 10-K filings project the generic market entry window on March 30, 2032 following Hatch-Waxman Paragraph IV patent settlements and pediatric exclusivity extensions.